Mr. Rashid Bux reports

BIOMARK PARTNERS WITH RUBIX LS TO ADVANCE BLOOD-BASED CANCER SCREENING IN UNDERSERVED COMMUNITIES

Biomark Diagnostics Inc. and Rubix LS have signed a strategic partnership to develop better diagnostic tools to enhance lung cancer screening and improve breast cancer screening program, especially for women with dense breasts and triple negative breast cancer (TNBC), by focusing on reaching underserved communities. This collaboration combines the innovative strengths of both organizations to develop accessible, non-invasive and accurate diagnostic solutions that promise to set new standards in early detection and personalized cancer treatment.

Breast and lung cancers are among the leading health challenges for women worldwide, with early detection being crucial for successful treatment outcomes. However, access to early screening and diagnostics remains a significant barrier, particularly in underserved communities. Recognizing this, Rubix LS and Biomark are dedicating their partnership to advancing cancer detection technologies and ensuring these innovations reach those most in need.

Rashid Bux, chief executive officer of Biomark, emphasized the importance of inclusivity in healthcare innovation, stating: "Over the past year, we have laid the groundwork for today's partnership through extensive interactions with members of underserved communities at major society meetings and individually. Our collaboration with Rubix LS is a step towards democratizing access to advanced health care solutions, bridging the health care equity gap and making early cancer detection a reality for everyone, regardless of their geographic or socioeconomic status."

The initiative will harness Rubix LS's strength as a culturally competent research catalyst, with CLIA/CAP clinical laboratory capacity to perform screening and conducting necessary clinical studies working in harmony with Biomark's expertise in translating blood-based biomarker research into laboratory-developed diagnostic tests (LDT) that are not only effective but also widely accessible. Central to this effort is the deployment of mobile diagnostics and telehealth services, meticulously designed to bridge the gap in health care access and extend advanced cancer screening technologies to remote and underserved communities. This approach underscores a commitment to equity, ensuring that state-of-the-art health care solutions reach all segments of the population, particularly those in areas traditionally neglected by advancements in medical technology.

"Through our partnership with Biomark, we are not just innovating for the sake of science but to make a real difference in communities where access to early cancer screening can be life-changing," said Reginald Swift, PhD, chief executive officer of Rubix LS. "Our mission is to ensure that our breakthroughs in diagnostics are accessible to all, particularly those in underserved areas who are most vulnerable."

This groundbreaking initiative to transform women's health is a call to action for the health care community to prioritize equity in access to preventive care and to invest in solutions that can reach and benefit all populations, especially those historically marginalized or overlooked. Rubix LS and Biomark are proud to lead this charge, aiming to inspire a global movement toward more inclusive health care practices.

About Biomark Diagnostics Inc.

Biomark is a liquid biopsy company developing a molecular diagnostic technology platform that leverages the power of metabolomics and machine-learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the presymptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. While the company's current focus is on the commercialization of its liquid biopsy test for early detection of lung cancer, it has plans to expand into other hard-to-detect and hard-to-treat cancers such as brain, head and neck, breast, and pancreatic cancers.

We seek Safe Harbor.